Eligible Customers must provide their Consultation email confirmation to DECIEM staff upon arrival
Most patients experience no adverse effects beyond improved sleep quality
More recently, the LixiPark trial (2023), a double-blind, randomized, placebo-controlled trial, used daily subcutaneous lixisenatide, another GLP-1 RA in 156 patients with early PD
Common research-planning structures use one subcutaneous dose per day with gradual titration
Cited in Reuters, Most patients using weight loss drugs like Wegovy stop within a year. July 11, 2023 Virta Vitals: Taking Americas Pulse on Nutrition and Weight Management McKenzie AL, Athinarayanan SJ, McCue JJ, Adams RN, Keyes M, McCarter JP, Volek JS, Phinney SD, Hallberg SJ